Webinar: Maximizing Biorepositories for Research & Drug Discovery

Date/Time: Tuesday, December 15, 2020 at 10am EST (3pm GMT/UK).

Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and challenges facing biorepositories and biobanks around the world seeking to maximize their resources for research and drug discovery. Whether the repository contains a small collection of samples or is a large-scale national or international repository, biobanking will continue to play a key role in accelerating the discovery and development of new drugs, as these efforts require access to a larger array of biological samples. At the same time, biobanks face a variety of challenges in meeting the different interests and unique needs of their collaborators and partners in order to support a growing number of research studies. Maximizing utility and sustainability are critical for the long-term success of biorepositories and biobanks.

This webinar will explore the enormous innovative potential for biobanks and biorepositories to support translational research using a variety of bio-sample types (tissue samples, tumor cells, DNA, RNA, blood samples) collected from population-based and/or disease-specific groups of individuals.

Join Professor Stephen Sawcer, University of Cambridge, Dept. of Clinical Neurosciences; Samantha Hutten, Staff Scientist, Michael J Fox Foundation for Parkinson’s Disease Research (MJFF); Gordon R. Bernard, MD, Executive Vice President for Research and Chief Research Officer, Vanderbilt University Medical Center (VUMC), and David Kavanagh, PhD, Director of Clinical Partnerships, Genuity Science in a live webinar on Tuesday, December 15, 2020 at 10am EST (3pm GMT/UK).

REGISTER TODAY

About Genuity Science
Genuity Science is a data, analytics and insights organization headquartered in Boston, Massachusetts, USA, with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity Science partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP-accredited, CLIA-certified genomics laboratories in Woburn, Massachusetts, USA and in Dublin, Ireland and is deeply committed to data stewardship and data governance across its global offices. For more information, see www.genuitysci.com.

Advertisement